Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings Inc (RVPH) focuses on developing novel therapies for central nervous system disorders and cardiometabolic diseases through its proprietary drug discovery platform. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access comprehensive coverage of Reviva's progress including clinical trial results, regulatory submissions, and strategic partnerships. Our curated news collection enables efficient tracking of the company's lead candidates like Brilaroxazine (RP5063) and RP1208 through critical development phases.
Key updates include progress in neuropsychiatric drug development, intellectual property advancements, and financial reporting. The resource serves investors requiring detailed insights into therapeutic pipeline maturation and market positioning within competitive CNS/pharma sectors.
Bookmark this page for streamlined access to Reviva's latest developments. Check regularly for authoritative reporting on clinical data releases, FDA communications, and research collaborations that shape the company's trajectory in biopharmaceutical innovation.
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced an upcoming late-breaking poster presentation at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting. The presentation will focus on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia treatment.
The presentation, scheduled for May 28, 2025, from 11:15 a.m. to 1 p.m. MT at the Fairmont Scottsdale Princess in Arizona, will be delivered by Dr. Laxminarayan Bhat, the company's Founder, President, and CEO. The poster will detail brilaroxazine's effects on efficacy, safety, adherence, and biomarkers in patients with stable schizophrenia during the Phase 3 RECOVER trial extension.
Reviva, a late-stage pharmaceutical company, is developing therapies targeting unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases.
Reviva Pharmaceuticals (NASDAQ: RVPH) reported its 2024 financial results and key developments for brilaroxazine, its late-stage schizophrenia treatment. The preliminary topline data from the open-label extension (OLE) trial showed sustained efficacy over one year with dose-dependent improvements in PANSS scores ranging from -15.2 to -20.8 points across different dosages.
The drug demonstrated favorable safety with no single side effect exceeding 5% and a low treatment-related adverse event rate of 15.2%. The company reported a net loss of $29.9 million ($0.90 per share) for 2024, compared to $39.3 million in 2023. Cash position stood at $13.5 million as of December 31, 2024.
Key upcoming milestones include full OLE trial data analysis in Q2 2025, initiation of Phase 3 RECOVER-2 trial in mid-2025, and targeted NDA submission in Q4 2026. The company completed an $18 million public offering in December 2024.
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced it will present topline data from the long-term open label extension portion of its Phase 3 RECOVER study for brilaroxazine in schizophrenia treatment at the 2025 SIRS Congress in Chicago.
The presentation, titled 'Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants,' will be delivered by Dr. Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals, on Sunday, March 30th from 10:30 AM to 12:00 PM CST.
The company, which focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, will showcase these results at the Schizophrenia International Research Society (SIRS) Congress, taking place March 29 to April 2, 2025.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update presentation at the virtual conference on Wednesday, February 12, 2025, at 2:40 p.m. ET. The event, scheduled for February 11-12, 2025, will be held entirely virtually, with a webcast link available for interested participants.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the 2025 BIO CEO & Investor Conference.
The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will be part of a panel discussion titled 'Tackling Mental Health through New Targets and Endpoints Progress'. The panel is scheduled for Tuesday, February 11, 2025, at 1:00 p.m. ET in New York, NY.
The conference will take place from February 10-11, 2025, and interested parties can register for the event and schedule one-on-one meetings with Reviva's management team.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit.
The company's Founder, President, and CEO, Dr. Laxminarayan Bhat, will deliver a webcasted presentation on Monday, January 13, 2025, at 12:30 p.m. ET. The virtual event will be accessible through the conference homepage at lythampartners.com/health2025/ or directly via the company-specific link.
Investors will have the opportunity to schedule one-on-one meetings following the event by contacting Lytham Partners representatives. A replay of the presentation will be made available through the same web links.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) has announced the pricing of an $18.0 million public offering, consisting of 12,000,000 shares of common stock along with warrants. The offering includes series A warrants to purchase up to 6,000,000 shares and series B warrants for up to 12,000,000 shares.
Each share is being sold at $1.50 with accompanying warrants. Series A warrants are exercisable immediately at $1.50 per share and expire in six months, while series B warrants, also at $1.50 per share, expire in five years. The offering is expected to close around December 18, 2024.
Citizens JMP is serving as the sole bookrunner. The company plans to use the proceeds for research and development activities, working capital, and general corporate purposes.
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced a proposed public offering of common stock (or common share equivalents) and warrants to purchase common stock. The company, which develops therapies for CNS, inflammatory, and cardiometabolic diseases, plans to use the proceeds for research and development activities and general corporate purposes.
Citizens JMP Securities is acting as the sole bookrunner for the offering, which will be conducted under a previously filed shelf registration statement. The final terms and size of the offering will depend on market conditions, with no guarantee of completion.
Reviva Pharmaceuticals announced positive preliminary topline data for the open-label extension (OLE) portion of its Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia. The study demonstrated that once-daily brilaroxazine showed favorable long-term safety and robust broad-spectrum efficacy over 1 year.
The drug was generally well-tolerated with low rates of adverse events and a discontinuation rate of 35%. All three doses (15 mg, 30 mg, 50 mg) were efficacious. Key findings include:
- 435 patients enrolled in the OLE
- 113 patients completed 1-year treatment
- Clinically meaningful decreases in PANSS scores: Total (-18.6), Positive (-5.2), and Negative (-4.5) symptoms
- No drug-related serious adverse events
- Common adverse events: weight increase (3.2%), insomnia (1.8%), somnolence (1.6%)
Full data from the OLE is expected in Q1 2025.
Reviva Pharmaceuticals reported Q3 2024 financial results and progress in its brilaroxazine clinical program for schizophrenia. The company announced that 108 patients have completed one year of treatment in the open-label extension (OLE) trial, with over 250 patients completing 6 months. Vocal biomarker speech latency data from the RECOVER trial supported brilaroxazine's efficacy for negative symptoms. The company reported a net loss of $8.4 million ($0.25 per share) for Q3 2024, compared to $11.3 million in Q3 2023. Cash position stood at $5.6 million as of September 30, 2024. Topline data from the OLE trial is expected in December 2024, with potential NDA submission targeted for Q2 2026.
